Portal de investigação
Intake of Proton-Pump Inhibitors and Gastric Cancer within the Stomach Cancer Pooling (StoP) Project
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Sassano, M
- Mariani, M
- Pelucchi, C
- Morais, S
- Martín, V
- Moreno, V
- Curado, MP
- Dias-Neto, E
- Leja, M
- Gasenko, E
- La Vecchia, C
- Boccia, S
- Pastorino, R
Unidades de investigação
Abstract
Background: A potential association between proton-pump inhibitors (PPI) and gastric cancer remains undefined. Thus, we aimed to evaluate such association within the Stomach cancer Methods: Data from five case-control studies of the StoP Project were included (1,889 cases and 6,517 controls). We assessed the impact of different exposure definitions, specifically any reported use of PPIs and exposure definitions based on the duration of PPI intake. Additionally, we modeled the dose-response relationship between the cumulative duration of PPI intake and gastric cancer. Results: Significant associations between PPI intake and gastric cancer, both overall and in the stratified analyses, were limited to exposure definitions based on short durations of intake. The overall odds ratio (OR) for any reported PPI intake was 1.78 [95% confidence interval (CI): 0.76-4.14]. In the dose-response analysis, the ORs of gastric cancer were found to be higher for short durations of PPI intake (6 months: OR 3.26; 95% CI: 2.40-4.42; one year: OR 2.14; 95% CI: 1.69-2.70; 2 years: OR 1.50; 95% CI: 1.22-1.85; 3 years: OR 1.27; 95% CI: 1.03-1.56), with the association becoming not significant for durations longer than 3 years. Conclusions: Our findings suggest that the observed association between PPIs and gastric cancer might be mainly due to reverse causality. Impact: The results of this study suggest that PPIs area safe thera-peutic choice regarding their effect on the occurrence of gastric cancer. See related commentary by Richman and Leiman, p. 1127
Dados da publicação
- ISSN/ISSNe:
- 1055-9965, 1538-7755
- Tipo:
- Article
- Páginas:
- 1174-1181
- Link para outro recurso:
- www.scopus.com
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION American Association for Cancer Research Inc.
Citações Recebidas na Web of Science: 1
Citações Recebidas na Scopus: 4
Documentos
- Não há documentos
Filiações
Keywords
- HEALTH-CARE; RISK-FACTOR; DELAY
Campos de estudo
Financiamento
Proyectos asociados
Breast cancer heterogeneity - etiology, clinical management, use of health resources and survival
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2022
Longitudinal Assessment of Cognitive Decline in Breast and Prostate Cancer Survivors
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico (Cognitive Decline) . 2022
Healthcare use among cancer patients and their partners in different phases of the cancer pathway
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2021
Reshaping organized cervical cancer screening: strategies to increase the adherence and reduce invitation costs
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2020
Using pooled analyses based on individual participant data for a finer assessment of gastric cancer etiology
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2020
RISK AND SURVIVAL OF GASTRIC CANCER RELATES SECOND PRIMARY TUMOURS: A COMPETING RISKS FRAMEWORK
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2019
Citar a publicação
Sassano M,Mariani M,Pelucchi C,Lunet N,Morais S,Martín V,Moreno V,Curado MP,Dias E,Leja M,Gasenko E,La Vecchia C,Boccia S,Pastorino R. Intake of Proton-Pump Inhibitors and Gastric Cancer within the Stomach Cancer Pooling (StoP) Project. Cancer Epidemiol. Biomarkers Prev. 2023. 32. (9):p. 1174-1181. IF:3,800. (2).
